Evidence map›Paper›PMID 33057993›Full record

ArticleMolecular biology reports2020

Chromosomal instability reducing effect of paclitaxel and lapatinib in mouse embryonic stem cells with chromosomal abnormality.

Banafsheh Mirzaei-Seresht, Masood Bazrgar, Masoud Sheidai, Seyedeh-Nafiseh Hassani, Najmeh Sadat Masoudi, Sepideh Mollammohammadi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Banafsheh Mirzaei-SereshtDepartment of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, No. 2, Hafez St., Banihashem St., Resalat Highway, P.O.Box:16635-148, Tehran, Iran.ORCID http://orcid.org/0000-0002-7823-1242
Masood BazrgarDepartment of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, No. 2, Hafez St., Banihashem St., Resalat Highway, P.O.Box:16635-148, Tehran, Iran. mbazrgar@royaninstitute.org.ORCID http://orcid.org/0000-0002-5453-9576
Masoud SheidaiDepartment of Genetics, Faculty of Biological Science, Shahid Beheshti University, Tehran, Iran.
Seyedeh-Nafiseh HassaniDepartment of Stem Cell and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.ORCID http://orcid.org/0000-0001-5047-8406
Najmeh Sadat MasoudiDepartment of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, No. 2, Hafez St., Banihashem St., Resalat Highway, P.O.Box:16635-148, Tehran, Iran.ORCID http://orcid.org/0000-0002-6337-6625
Sepideh MollammohammadiDepartment of Stem Cell and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.ORCID http://orcid.org/0000-0003-3389-8833
Royan Institute · IRShahid Beheshti University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chromosomal abnormalities, as a frequent phenomenon in cultured embryonic stem cells (ESCs), is a major obstacle in the ESC application in regenerative medicine. Recent studies showed that aneuploid embryonic stem cells of humans and mice are more vulnerable to anticancer drugs, compared with normal cells. The aim of the current study was to evaluate effects of three anticancer drugs, paclitaxel, lapatinib and bortezomib, on mouse embryonic stem cells (mESCs) as a suitable and available model. To assess in vitro cell toxicity, two mESC lines were treated with the aforementioned drugs. Using G-band karyotyping and micronucleus assay, the effect of anticancer drugs in terms of reduction of chromosomal instability in the mESCs was evaluated in control and treatment groups. Also, apoptosis rate of both groups was estimated by FITC-Annexin V/Propidium Iodide (PI) double staining. In addition, the effect of these three drugs in maintaining the pluripotency was assessed through alkaline phosphatase assay and quantification of the expression of three key pluripotency genes, Nanog, Pou5f1 and Sox-2 was performed using Real Time PCR. The rate of numerical abnormalities after treatment with paclitaxel and lapatinib was lower than the control group. The expression level of pluripotency genes exhibited no significant difference between control and treatment groups. Administration of paclitaxel and lapatinib to the mESCs culture at an appropriate dose and in a timely manner could decrease chromosome stability without affecting pluripotency.

Indexed as

AnimalsAntineoplastic AgentsApoptosisBortezomibCell LineChromosomal InstabilityLapatinibMiceMouse Embryonic Stem CellsNanog Homeobox ProteinOctamer Transcription Factor-3PaclitaxelSOXB1 Transcription FactorsAntineoplastic AgentsBortezomibLapatinibNanog Homeobox ProteinNanog protein, mouseOctamer Transcription Factor-3PaclitaxelPou5f1 protein, mouseSox2 protein, mouseSOXB1 Transcription FactorsBortezomibChromosomal instabilityLapatinibMouse embryonic stem cellsPaclitaxel

Identifiers

PMID33057993
OpenAlexW3093128685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.